Dexamethasone Treatment of Congenital Adrenal Hyperplasia
NCT00621985
Completed
The purpose of this study is to determine if dexamethasone given at night is a more effective treatment for congenital adrenal hyperplasia in young children than standard three times per day hydrocortisone. Our hypothesis is that nocturnal dexamethasone will lead to more efficient suppression of the hypothalamic-pituitary-adrenal axis. We performed a cross-over trial comparing hormonal control during two 24-hour hospitalizations, one on hydrocortisone and one on nocturnal dexamethasone.
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
01/26/2011
Locations: Children's Hospital Boston, Boston, Massachusetts
Conditions: Adrenal Hyperplasia, Congenital
Register for Updates
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
NCT00694135
Completed
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
08/27/2010
Locations: Ophthalmic Consultants of Boston, Boston, Massachusetts +1 locations
Conditions: Uveitis, Anterior
Register for Updates
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates